Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 19/20 | 0.72 |
| ▸ | ICAM1 | P05362 | 19/20 | 0.72 |
| ▸ | ITGAL | P20701 | 19/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992562 | 0.93 | ITGB2 (0.63) | ITGB2ICAM1ITGALHDAC6 | |
| SCHEMBL16867300 | 0.86 | HDAC6 (0.56) | ITGB2ICAM1ITGALHDAC6 | |
| SCHEMBL13813571 | 0.84 | ITGB2 (0.72) | ITGB2ICAM1ITGAL | |
| SCHEMBL10129644 | 0.83 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL13658130 | 0.83 | ITGB2 (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL13813604 | 0.82 | ITGB2 (0.87) | ITGB2ICAM1ITGAL | |
| SCHEMBL4755973 | 0.82 | ITGB2 (0.76) | ITGB2ICAM1ITGAL | |
| SCHEMBL13813601 | 0.82 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL18868505 | 0.82 | ITGB2 (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL13658128 | 0.82 | ITGB2 (1.00) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3797775-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| EP-3167886-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | NOVARTIS AG (CH) | 2020-08-05 | — | — | EP | disclosed |
| EP-3167886-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | SARcode Bioscience Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2209371-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-8168655-B2 | Compositions and methods for treatment of eye disorders | SARCODE BIOSCIENCE INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168655-B2 | Compositions and methods for treatment of eye disorders | SARCODE BIOSCIENCE INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009054914-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.